Andrew Partheniou


Recent Articles

Biotech at Good Entry Point for Investors, Analyst Says 12/20/2022

The company, focused on psychedelic-assisted psychotherapies to better treat addiction, is worth more than the CA$10 million the market is valuing it at, noted a Stifel report.

Co. Pursuing Ketamine for Addiction Forms Partnership 08/16/2022

In landing this first licensing deal, the life sciences firm "shows good progress towards a potentially high-margin business," noted a Stifel report.

Analyst Sees 'Attractive Long-Term Economics' for Healthcare Co. 07/13/2022

One healthcare company with upcoming catalysts wants to take a share of the CA$6-billion alcoholism treatment market with its proprietary psychedelic-assisted psychotherapy treatments.

Recent Quotes

"AWKN announced its first KARE licensing agreement."

— Andrew Partheniou, Stifel (8/15/22)
more >

"AWKNF shares offer an attractive risk-reward profile."

— Andrew Partheniou, Stifel (3/31/22)
more >

Due to permission requirements, not all quotes are shown.